http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020144385-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6a9851d9bc2d1914ed877532b42e78b2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-26 |
| filingDate | 2020-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45096d401c7d52d7128c4bbf92d380af |
| publicationDate | 2020-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2020144385-A1 |
| titleOfInvention | Use of an iron agent for the treatment of atrial fibrillation |
| abstract | The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to use of an iron agent for the improvement of atrial electrophysiology (e.g., heart failure, hypertension, heart valve disease, coronary artery disease, obesity, or diabetes mellitus) for the management of atrial fibrillation or a disorder associated with atrial fibrillation in an animal; for the reduction of P-wave dispersion/duration for the management of atrial fibrillation or a disorder associated with atrial fibrillation in an animal; and use of an iron agent in a method for preventing or treating atrial fibrillation (e.g., paroxysmal, persistent, long- standing, or chronic atrial fibrillation) in an animal (e.g., a mammal, e.g., a human). Examples of iron agents include ferrous sulphate, ferrous fumarate, ferrous gluconate, iron polysaccharide, iron polymaltose, high molecular weight iron dextran, low molecular weight iron dextran, iron sucrose, ferrous gluconate, ferric carboxymaltose, and iron isomaltoside; and iron(III) isomaltoside (also known as ferric derisomaltose), iron(III)- hydroxide dextran complex, and ferumoxytol. Commercially available iron agents include Monofer®, Diafer®, Cosmofer®, Uniferon®, and Feraheme®. |
| priorityDate | 2019-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 81.